汤虎成　曾慧

[摘要] 目的 比较美罗华联合CHOP方案和单后CHOP方案治疗弥漫大B细胞性淋巴瘤的疗效。方法 整群选取2009年1月—2015年7月期间该院及南京鼓楼医院血液科收治的弥漫大B细胞性淋巴瘤患者60例，将其随机分为观察组与对照组，每组各30例。对照组单用CHOP方案进行治疗，观察组患者在此基础上联合美罗华共同治疗，对两组患者的临床疗效进行对比。结果 观察组完全缓解12例、部分缓解12例，其治疗总有效率为80%；对照组完全缓解8例、部分患者11例，其治疗总有效率为63.3%，组间比较差异具有统计学意义（P<0.05）。观察组患者1年总生存率为86.7%，对照组患者1年总生存率为73.3%，组间比较差异具有统计学意义（P<0.05）。结论 美罗华联合CHOP方案治疗弥漫性大B细胞淋巴瘤临床效果优于单用CHOP方案治疗。

[关键词] 美罗华；CHOP方案；弥漫性大B细胞淋巴瘤；临床疗效

[中图分类号] R5 [文献标识码] A [文章编号] 1674-0742（2015）11（c）-0019-02

[Abstract] Objective To compare the effect of rituximab in combination with CHOP regimen and CHOP regimen alone in the treatment of diffuse large B-cell lymphoma. Methods 60 cases with diffuse large B-cell lymphoma admitted in Department of Hematology of The People's Hospital of Luhe and Nanjing Drum Tower Hospital from January 2009 to July 2015 were selected and randomly divided into the observation group and the control group with 30 cases in each. Patients in the control group were treated by CHOP regimen， and those in the observation group were treated by CHOP regimen combined with rituximab. And the clinical efficacy was compared between the two groups. Results In the observation group， 12 cases had complete remission， 12 cases had partial remission， the overall response rate was 80%， in the control group， 8 cases had complete remission， 11 cases had partial remission， the overall response rate was 63.3%， the differences between the two groups were statistically significant（P<0.05）. The overall 1-year survival rate was 86.7% in the observation group， and 73.3% in the control group， the difference between the two groups was statistically significant（P<0.05）. Conclusion Rituximab combined with CHOP regimen has better effect than CHOP regimen alone in the treatment of diffuse large B-cell lymphoma.

[Key words] Rituximab； CHOP regimen； Diffuse large B-cell lymphoma； Clinical efficacy

弥漫性大B淋巴瘤是常见的成人非霍奇金淋巴瘤亚型，该病发病率约占30%～40%[1]。临床上主要以化疗方法为主，并以CHOP 方案最为常用，但随着临床多项追踪研究发现，单用CHOP方案患者的5年生存率仅为40%～50%，未能达到理想的效果[2-4]。因此临床上致力于寻找其他治疗方案以提高临床疗效。在该次调查中，该院整群选取2009年1月—2015年7月收治的弥漫大B细胞性淋巴瘤患者60例，将分析美罗华联合CHOP方案对弥散性淋巴瘤的治疗效果，现报道如下。

1 资料与方法

1.1 一般资料

整群选取2009年1月—2015年7月期间该院及南京鼓楼医院收治的弥漫大B细胞性淋巴瘤患者60例，将其随机分为观察组与对照组，每组30例。观察组男20例、女10例，患者年龄为30～69岁，平均（44.1±2.4）岁；生发中心型12 例，非生发中心型18例。对照组男19例、女11例，患者年龄为30～69岁，平均30～69岁，平均（45.2±2.5）岁，生发中心型11例，非生发中心型19例。……